Nello Mainolfi, Ph.D., is the Founder, President, and Chief Executive Officer of Kymera Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel small molecule medicines that address the underlying causes of diseases by harnessing the body's natural protein degradation processes. Dr. Mainolfi's journey in the biopharmaceutical industry began with his strong academic background; he earned his Ph.D. in Organic Chemistry from the University of Naples Federico II in Italy. His passion for drug discovery and development led him to further his expertise through postdoctoral research at the Massachusetts Institute of Technology (MIT), where he worked under the guidance of renowned scientists in the field. Before founding Kymera Therapeutics, Dr. Mainolfi held significant roles at several leading pharmaceutical companies, including Novartis and Millennium Pharmaceuticals, where he contributed to the development of innovative drug candidates. His extensive experience in medicinal chemistry and drug discovery laid the foundation for his vision to establish Kymera Therapeutics. Under his leadership, Kymera has become a pioneer in the field of targeted protein degradation, a revolutionary approach that has the potential to treat a wide range of diseases, including cancer and autoimmune disorders. Dr. Mainolfi's strategic direction and commitment to scientific excellence have been instrumental in advancing Kymera's pipeline and securing partnerships with major pharmaceutical companies. As the President and CEO of Kymera Therapeutics, Dr. Mainolfi oversees the company's overall operations and strategic initiatives. He plays a crucial role in guiding the research and development efforts, ensuring that Kymera remains at the forefront of the targeted protein degradation field. His leadership has been recognized by the industry, with Kymera receiving numerous accolades and awards for its innovative approach to drug discovery. Dr. Mainolfi's dedication to improving patient lives through cutting-edge science continues to drive Kymera's mission to develop transformative medicines.